Related Experiment Video
Updated: May 9, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[Analysis of multicenter efficacy of acute lymphoblastic leukemia in older children]
Hui Jiang1, Jing-yan Tang, Na Zhang
1Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200040, China.
Insights
This study evaluated the ALL-2005 protocol for older children with acute lymphoblastic leukemia (ALL). The ALL-2005 regimen showed promising outcomes, but BCR-ABL translocation indicates a poorer prognosis in these patients.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Trial Analysis
Context:
- Acute lymphoblastic leukemia (ALL) in older children (10-18 years) presents unique challenges.
- Evaluating multicenter cooperation regimens is crucial for optimizing treatment strategies.
- The ALL-2005 protocol was implemented across five centers for newly diagnosed ALL patients.
Purpose:
- To retrospectively analyze clinical characteristics of older children diagnosed with ALL.
- To evaluate treatment outcomes, including event-free survival (EFS) and overall survival (OS), using the ALL-2005 protocol.
- To identify prognostic factors influencing survival in this patient cohort.
Summary:
- The study included 103 newly diagnosed ALL patients (aged 10-18 years) treated with the ALL-2005 protocol.
- Achieved a 94.2% complete remission rate; however, 36.9% of patients died during treatment.
- The 5-year EFS and OS were 60.2% and 64.1%, respectively. Age (14-18 years) and BCR-ABL translocation were identified as independent risk factors for poorer EFS.
Impact:
- The ALL-2005 protocol demonstrates feasibility and provides valuable survival data for older childhood ALL.
- Identifies specific risk factors (age, BCR-ABL translocation) crucial for risk stratification and personalized treatment.
- Recommends the ALL-2005 protocol for older childhood ALL, emphasizing the need for intensified therapy in high-risk cases.
Objective:
To retrospectively analyze the clinical characteristics and the treatment outcomes of older children with acute lymphoblastic leukemia (ALL), and to evaluate the multicenter cooperation regimen (ALL-2005).
Methods:
The clinical data of 103 newly diagnosed ALL children aged 10 to 18 years old from five hospitals were enrolled in this study. They were all received ALL-2005 protocol. The clinical characteristics, the event-free survival (EFS), the overall survival (OS) and the prognostic analysis were evaluated.
Results:
(1) Of the 103 patients, 62 were boys and 41 girls, with a median age of 12.3 years old. According to immunophenotyping, 90 (87.4% ) of 103 patients were diagnosed as B-ALL and 13 (12.6%) as T-ALL. According to risk factor, 65 (63.1%) were in intermediate risk group (MR-ALL) and 38 (36.9%) in high risk group (HR-ALL). Central nervous system leukemia (CNSL) happened in 4 (3.9%) patients at diagnosis. Of the 89 patients received chromosome test, 58 (65.2%) obtained the test results, including 21(36.2%) with aberrational chromosomes and 37 (63.8%) with normal karyotype. Of 81 patients received molecular biological test, 16 (19.8%) were positive for fusion gene. (2) After induction therapy, 97 (94.2%) obtained complete remission (CR). Twenty-eight patients relapsed with a median time of 11.9 months (ranged 2.9-57.8 months), and 38 (36.9%) patients died during the treatment. As of September 30, 2012, the median follow-up was 47 months (ranged 0.4-92.6 months). The 5-year EFS and 5-year OS of ALL patients were (60.2 ± 4.8)% and(64.1 ± 4.7)%. The 5-year EFS of MR-ALL and HR-ALL were (73.8 ± 5.5)% and (31.6 ± 8.3)% (P<0.01), the 5-year OS of MR- ALL and HR-ALL were (78.5 ± 5.1)% and (35.9 ± 8.0)% (P<0.01), respectively. (3) Cox proportion hazard regression model analysis indicated that age of 14-18 years old and BCR- ABL translocation or t(9;22) were independent risk prognostic factor for 5-year EFS.
Conclusion:
The incidence and prognosis in older childhood ALL were related with age, risk and biological characteristics. BCR-ABL translocation or t(9;22) was the risk factor of prognosis. ALL- 2005 protocol was recommended as the regimen for older childhood ALL.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism
